The key players of the Global COPD and asthma drugs market are employing novel concepts and ideas to improve, manage and control asthma & COPD, and also enhance their profitability so as to gain a competitive edge over the other market players. Seretide/Advair, Symbicort, and Singular were leading brands and accounted for around one-fourth share in world COPD and asthma drugs market.
Global Asthma and COPD Drugs Market was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022, according to a new report published by Allied Market Research. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted around for around half of the Global Asthma and COPD Drugs market share in 2015.
This report covers information on various types of medication class to treat asthma and COPD in compliance with the European Medical Association (EMA), the U.S. Food and Drugs Administration (FDA), Conformité Européene (CE) and other regulatory authorities. Moreover, this study on the global Asthma and COPD Drugs also focuses on the treatment of the disease which is available in the market.
Get the PDF brochure of this market study: https://www.alliedmarketresearch.com/request-sample/311
The Global Asthma and COPD Drugs market is segmented based on disease, medication class and geography. Based on disease, the market is categorized into asthma and COPD. Based on medication class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. North America holding major share of the market.
The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of this market. The market is driven by the growing patient COPD and asthmatic population, as well as FDA approvals for the novel products and its wide acceptance among the patient population. Increasing government initiatives to control COPD and asthma further fuel the growth for this market.
The Asthma and COPD Drug market consists of medication class based on the severity of the disease. Short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids(ICS), leukotriene antagonists (LTA), combination products, anticholinergics and others are the medication class which are used in the treatment of COPD and asthma.
The disease segment consists of the global prevalence of asthma and COPD for market sizing and forecasting the global sales of the Asthma and COPD Drugs. Asthma contributed the highest share, approximately 66.1%, to the world Asthma and COPD Drugs market with the expected to grow at a highest CAGR of 1.3% by 2022.
The growth of the North American and European market is driven by the increasing COPD and asthma patient population and rising number of smokers. North American Asthma and COPD Drugs market is likely to register a CAGR of 3.2% over the analysis period, which would create potential opportunities for new market players to grow.